Sign up
Pharma Capital

Collagen Solutions emerges from 'challenging' year in stronger position

Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy and CFO Hilary Spence discuss with Proactive Investors the firm's results for the year ended 31 March 2018.

The loss of contracts with four key customers – valued at over £800,000 a year – meant revenue slipped 6% to £3.83mln in the 12 months ended March 31 (2017: £4.09mln).

In response to the challenges, Collagen set about restructuring its business to bolster cash, improve margins and solidify the trajectory to profitability.

They've also been busy strengthening the board and executive team to help boost commercial expertise.

 

View full COS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.